Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics
The new cancer diagnostic test is intended to identify patients more likely to benefit from a specific treatment. The collaboration will draw on Dako's extensive experience within the development of cancer diagnostic tests and OSI Pharmaceuticals' thorough knowledge in developing and commercializing novel pharmaceutical products.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.